PharmaLytica 2021 Hyderabad review.

GMP Deficiencies in Packaging

A US-American pharmaceutical manufacturer has recently received a Warning Letter from the FDA due to deficiencies in packaging and quality assurance. Complaints were made regarding line clearance, cleaning of the equipment and investigation of deviations. During the inspection, which took place in February and March, the FDA noticed inadequate line clearance.

The pharmaceutical manufacturer, who works as a repackager, had indicated in batch records that the line clearance had been carried out. However, the FDA had actually noticed numerous tablets and capsules on and below the packaging lines. The manufacturer had indicated that they would improve line clearance and re-train their staff. However, the FDA complained that the response did not include an SOP for line clearance. Another SOP for the cleaning of the production areas - according to FDA - lacks necessary details.

FDA lacks evidence that product residues are sufficiently removed from the multipurpose equipment. In its cleaning validation, the manufacturer had used the most powdery product and considered this to be a validation for other products in a worst-case consideration. This is understandably not sufficient for the FDA. The FDA now expects a cleaning validation programme that addresses issues such as toxicity of the products, solubility of the products in the cleaning medium, products that are difficult to clean, definition of wipe test points in the equipment that are difficult to clean and maximum service life before cleaning is required again.


This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More